{"nctId":"NCT00104234","briefTitle":"Study of rhASB in Patients With Mucopolysaccharidosis VI","startDateStruct":{"date":"2004-02"},"conditions":["Mucopolysaccharidosis VI"],"count":39,"armGroups":[{"label":"rhASB/rhASB","type":"OTHER","interventionNames":["Drug: N-acetylgalactosamine 4-sulfatase"]},{"label":"Placebo/rhASB","type":"OTHER","interventionNames":["Drug: Placebo/rhASB"]}],"interventions":[{"name":"N-acetylgalactosamine 4-sulfatase","otherNames":["rhASB"]},{"name":"Placebo/rhASB","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patient consent\n* Patient must have successfully completed study ASB-03-05, including having received at least 20 of 24 scheduled weekly infusions and having missed no more then two consecutive infusions\n* If female of childbearing potential, patient must have a negative pregnancy test\n\nExclusion Criteria:\n\n* Pregnant or lactating patient\n* Patient has received an investigational drug within 30 days prior to study enrollment\n* Patient is unwilling or unable to travel to the primary site for periodic assessments","healthyVolunteers":false,"sex":"ALL","minimumAge":"7 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"12-Minute Walk Test","description":"Mean change in meters walked in 12 minutes. Mean change is the mean difference between the 12-Minute Walk Test at 96 weeks and that measured before first ever treatment with rhASB. For the rhASB/rhASB group, mean change is calculated for Week 96 - Baseline. For the placebo/rhASB group, mean change is calculated for Week 96 - Week 24.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"187","spread":"187"},{"groupId":"OG001","value":"118","spread":"127"}]}]}]},{"type":"SECONDARY","title":"3-Minute Stair Climb","description":"Mean change in number of stairs climbed per minute in 3 minutes. Mean change is the mean difference between the 3-Minute Stair Climb at 96 weeks and that measured before first ever treatment with rhASB. Mean change is calculated for Week 96 - Baseline for the rhASB/rhASB group and for Week 96 - Week 24 for the placebo/rhASB group.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.1","spread":"16.1"},{"groupId":"OG001","value":"11.1","spread":"10.0"}]}]}]},{"type":"SECONDARY","title":"Change in Urinary Glycosaminoglycans (GAG) Level","description":"Mean change in urinary GAG level for the first 72 weeks of rhASB treatment. For the rhASB/rhASB group, mean change was calculated for Week 72 -Baseline. For the placebo/rhASB, mean change was calculated for Week 96 - Week 24.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-231","spread":"91"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":14,"n":38},"commonTop":["Cough","Headache","Pyrexia","Diarrhoea","Athralgia"]}}}